The bioburden testing is also called as microbial enumeration test or microbial load test. The test is performed to examine the microbial content in raw materials, in-process samples, and finished product in the pharmaceutical, and medical device industry among others. The test are done with the methods which includes membrane filtration, direct plating and most probable number (MPN).

The bioburden testing market is anticipated to grow in the forecast period owing to key factors such as rise in the manufacturing of the medical devices and biopharmaceutical and pharmaceutical drugs. The rise in the expenditure for the healthcare industry are likely to robust the growth of the market. The increase in the CROs are likely to create growth opportunities in the forecast period.

The "Global Bioburden Testing Market Analysis to 2028" is a specialized and in-depth study of the biotechnology industry with a focus on the global market trend. The report aims to provide an overview of global bioburden testing market with detailed market segmentation by product, type of test, application, end user and geography. The global bioburden testing market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading bioburden testing market players and offers key trends and opportunities in the market.

The global bioburden testing market is segmented on the basis of product, type of test, application and end user. Based product, the market is segmented as instruments and consumables. Based on the type of test, the market is classified as anaerobic count test, aerobic count test, spore count test and mold count test. On the basis of application, the market is divided as medical device testing, in-process material testing, raw material testing and others. Based on the end user, the market is segmented as medical device manufacturers, pharmaceutical & biotechnology companies, contract manufacturing organizations and others.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global bioburden testing market based on product, type of test, application and end user. It also provides market size and forecast till 2028 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The bioburden testing market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.

North America is expected to contribute to the largest share in the bioburden testing market in the forecast period, due to the extensive manufacturing of the medical devices, innovative biopharmaceuticals and pharmaceutical products and others. Europe is expected to be second largest market and Asia Pacific is expected to be the fastest growing market owing to the rise in the manufacturing generic drugs and rise in the healthcare expenditure.

The report analyzes factors affecting bioburden testing market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the bioburden testing market in these regions.

The report also includes the profiles of key bioburden testing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the bioburden testing market include, Thermo Fisher Scientific Inc., Merck KGaA, bioM?rieux SA, BD, QIAGEN, SGS SA, Pacific BioLabs, Nelson Laboratories, LLC, Charles River and STERIS.